BioDelivery Sciences International (BDSI) : Analyst Rating Update

BioDelivery Sciences International (BDSI) : The consensus on BioDelivery Sciences International (BDSI) based on 7 analyst recommendation on the company stock is 1.57, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

BioDelivery Sciences International (BDSI) : Currently there are 7 street experts covering BioDelivery Sciences International (BDSI) stock. The most bullish and bearish price target for the stock is $16 and $4 respectively for the short term. The average price target of all the analysts comes to $7.43. The estimated standard deviation from the target is $4.2.

BioDelivery Sciences International (NASDAQ:BDSI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.33 and $2.24 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.81. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.44, notching a gain of 3.83% for the day. The total traded volume was 1,876,582 . The stock had closed at $2.35 on the previous day.

Also, Major Brokerage house, Cantor Fitzgerald downgrades its ratings on BioDelivery Sciences International (NASDAQ:BDSI). In the latest research report, Cantor Fitzgerald lowers the target price from $9 per share to $5 per share. According to the latest information available, the shares are now rated Hold by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on May 11, 2016. The company shares have dropped -71.41% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $9.91 and the one year low was seen on May 23, 2016. The 50-Day Moving Average price is $2.32 and the 200 Day Moving Average price is recorded at $3.30.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.